Invention Grant
- Patent Title: Factor VIIa-polysialic acid conjugates having prolonged in vivo half-life
-
Application No.: US14946286Application Date: 2015-11-19
-
Publication No.: US10251941B2Publication Date: 2019-04-09
- Inventor: Peter Turecek , Juergen Siekmann , Friedrich Scheiflinger , Michel Canavaggio
- Applicant: BAXALTA INCORPORATED , BAXALTA GMBH
- Applicant Address: US IL Bannockburn CH Zug
- Assignee: Baxalta Incorporated,Baxalta GmbH
- Current Assignee: Baxalta Incorporated,Baxalta GmbH
- Current Assignee Address: US IL Bannockburn CH Zug
- Agency: Morgn, Lewis & Bockius LLP
- Main IPC: A61K38/48
- IPC: A61K38/48 ; C12N9/64 ; C12N9/96 ; A61K47/54 ; A61K47/61

Abstract:
The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
Public/Granted literature
- US20160129121A1 FACTOR VIIA-POLYSIALIC ACID CONJUGATES HAVING PROLONGED IN VIVO HALF-LIFE Public/Granted day:2016-05-12
Information query
IPC分类: